Spots Global Cancer Trial Database for Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Official Title: A Phase II Study of Chemotherapy Treatment Based on Molecular Profiling Diagnosis for Patients With Carcinoma of Unknown Primary Site
Study ID: NCT00737243
Conditions
Study Description
Brief Summary: This is a non-randomized Phase II study. Patients determined at initial diagnosis to have a carcinoma of unknown primary site (CUP) will have their treatment selected with the use of a molecular profiling assay. The assay will be performed on paraffin-embedded tumor tissue from a biopsy specimen. Patients given specific diagnoses (e.g., lung, pancreas, colon, breast, renal cell, prostate and ovarian cancer) will receive treatment regimens of proven activity. If no specific diagnosis is made with the molecular profiling assay, empiric chemotherapy with paclitaxel, carboplatin, bevacizumab and erlotinib will be administered.
Detailed Description: The primary objective of the study is evaluate the impact of the molecular assay prediction on the efficacy of therapy for patients with carcinoma of unknown primary site (CUP). Investigators will use tumor profiling results to direct standard, site-specific first-line therapy for patients with CUP.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Oncology Specialties (Clearview Cancer Institute), Huntsville, Alabama, United States
Florida Cancer Specialists, Fort Myers, Florida, United States
Integrated Community Oncology Network, Jacksonville, Florida, United States
Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, United States
Florida Hospital Cancer Institute, Orlando, Florida, United States
Northeast Georgia Medical Center, Gainesville, Georgia, United States
Wellstar Cancer Research, Marietta, Georgia, United States
Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States
Baptist Hospital East, Louisville, Kentucky, United States
Hematology Oncology Clinic, LLP, Baton Rouge, Louisiana, United States
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States
Jackson Oncology Associates, Jackson, Mississippi, United States
Nebraska Methodist Cancer Center, Omaha, Nebraska, United States
Hematology Oncology Associates of Northern NJ, Morristown, New Jersey, United States
Oncology Hematology Care, Cincinnati, Ohio, United States
Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Center for Cancer and Blood Disorders, Ft. Worth, Texas, United States
Virginia Cancer Institute, Richmond, Virginia, United States
Contact Details
Name: John D Hainsworth, M.D.
Affiliation: SCRI Development Innovations, LLC
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
